期刊文献+

高效液相色谱法测定琥珀酸曲格列汀片的含量 被引量:2

Determination of the Content of Trelagliptin Succinate Tablets by HPLC
下载PDF
导出
摘要 目的建立琥珀酸曲格列汀片含量测定的高效液相色谱方法。方法采用安捷伦C18(250mm×4.6mm,5μm)色谱柱;以甲醇-0.05mol·L-1磷酸二氢钾缓冲液(取磷酸二氢钾6.8g,加水溶解并稀释至1000m L,加三乙胺2m L,用磷酸调节p H值至5.5)(30∶70)为流动相,流速:1.0m L·min-1,检测波长277nm。结果琥珀酸曲格列汀的线性范围为20-200μg·m L-1,r=1.0000,平均回收率为99.5%,RSD为0.58%(n=9)。结论该方法简便灵敏、结果准确,适用于琥珀酸曲格列汀片的质量控制。 OBJECTIVE To establish a HPLC method for the determination of Trelagliptin Succinate tablets. METHODS Agilent C18column( 250 mm × 4. 6mm,5μm) was selected,with a mobile phase consists of methanol-0. 05mol·L- 1potassium dihydrogen phosphate buffer solution( potassium dihydrogen phosphate 6. 8g,add water dissolved and diluted to 1000 m L,add 2m L of triethylamine,using phosphoric acid to adjust the p H to 5. 5)( 30∶70),The flow rate was 1. 0m L·min- 1and the detection wavelength was 277 nm. RESULTS The calibration curve was proved to be linear in the range of 20 - 2000μg·m L- 1( r = 1. 0000). The average recovery was 99. 5%,RSD = 0. 58%( n = 9). CONCLUSION The method is accurate and reliable,and can be used for quality control of Trelagliptin succinate tablets.
作者 李广禄
出处 《海峡药学》 2015年第12期48-50,共3页 Strait Pharmaceutical Journal
关键词 琥珀酸曲格列汀 HPLC 含量测定 Trelagliptin Succinate HPLC Content Determination
  • 相关文献

参考文献3

二级参考文献33

  • 1Ludescher J, Wieser J, Laus G, et al. Process for thepre- paration of alogliptin and its benzoate salts: WO, 2010072680[P].2010-07-01.
  • 2International Diabetes Federation. IDF Diabetes Atlas,56th[EB/OL).[2013-12-10).http://www.idf.org/sites/default/files/EN _ 6E_Atlas_ FulI_O.pdf.
  • 3PhRMA. Report (20 (3): Medicines in development for older Americans[RlOL ).[2013-12-1 O).http://www.phrma. org/sites/defaultl files/pdf/oac20 13.pdf.
  • 4PhRMA.2014 Report: Medicines in Development for Diabetes[R/ OL).[20 14-02-20).http://www. phrma.org/ sites/default/ files/pdf/ diabetes2014.pdf.
  • 5Toscano D. The market for type 2 diabetes therapeutics - dey findings from a recent analysis of global drug development efforts[EB/OL).[20 14-0 1-IS].http://www.drugdeliverytech.com/Main/Back-Issues/ MARKET-BRLEF- The-Market-for- Type-2-Diabetes- Therap-64I.aspx.
  • 6Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen,CD26[J].Science, 1993,261(5120):465-469.
  • 7Ghatak S B, Patel D S, Shanker N, et al. Alogliptin: a novel molecule for improving glycemic control in type U diabetes mellitus[J].Curr Diabetes Rev,20 I 0,6(6):41 0-421.
  • 8White W B, Cannon C P, Heller S R, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J].N Engl J Med,2013,369(14): 1327-1335.
  • 9Novartis International AG. Novartis Q3 and 9M 2013 Condensed Interim Financial Report - Supplementary Data[EB/OL).[20 13-1 0- 21].http://www.novartis.com/downloads/investorsifinanciaI-resultsi quarterly-resultsl20 13-1 O-interim-financial-report-en.pdf.
  • 10Holst J 1. The physiology of glucagon-like peptide I[J].Physiol Rev,2007,S7(4): 1409-1439.

共引文献7

同被引文献7

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部